Market Study on Postoperative Pain Management: North America to Remain Leading Regional Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,900	245 Pages	Future Market Insights	February, 2022	FMARI17067362

Best Price Guarantee
Price	from $4,900
Length	245 Pages
Publisher	Future Market Insights
Published Date	February, 2022
SKU	FMARI17067362

Market Study on Postoperative Pain Management: North America to Remain Leading Regional Market

Postoperative Pain Management Market: Report Scope

The latest revised publication by Persistence Market Research on the global postoperative pain management market evaluates the opportunities and current market landscape, provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on key market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2031.

Important indicators for the successful growth of the postoperative pain management market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in this research. This research study can support readers to know the demand and quantitative development opportunities during the study period.

The research is beneficial opportunities for shareholders in the postoperative pain management market, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in this market space. Insights and wisdom presented in this study can be leveraged by shareholders in the postoperative pain management market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the market are also included in the current study. Depending on the potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Segments of Market

Persistence Market Research’s study on the postoperative pain management market offers information divided into four important segments - drug class, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Class

Opioids
NSAIDs
Local Anesthetic
Acetaminophen
Route of Administration

Injectable
Oral
Topical
Transdermal
Others
Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Clinics
Others
Region

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for postoperative pain management?
Which factors will induce a change in the demand for postoperative pain management during the assessment period?
How will changing trends impact the market?
How can market players capture the low-hanging opportunities in developed regions?
How has COVID-19 impacted the postoperative pain management industry?
What are the winning strategies of stakeholders to upscale their position in this landscape?
What are the restraints that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends in postoperative pain management sectors that will impact the market?
How can businesses in the market avail the of growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the postoperative pain management market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the postoperative pain management market and makes projections on the growth prospects of the market more accurate and reliable in the study report

Companies Mentioned

Teva Pharmaceutical Industries Ltd.
Novartis AG
Allergan plc
Mylan N.V
Pfizer Inc.
Purdue Pharma L.P
Janssen Pharmaceuticals, Inc.
Endo International plc
Pacira Pharmaceuticals Inc.
Egalet Corporation
GlaxoSmithKline Plc.

1. Executive Summary: 1.1. Global Market Outlook; 1.2. Demand Side Trends; 1.3. Supply Side Trends; 1.4. Analysis and Recommendations
2. Market Overview: 2.1. Market Coverage / Taxonomy; 2.2. Market Definition / Scope / Limitations
3. Key Market Trends: 3.1. Key Trends Impacting the Market; 3.2. Product Innovation / Key Development Trends
4. Market Background: 4.1. Macro-Economic Factors; 4.1.1. Global GDP Growth Outlook; 4.1.2. Global Healthcare Expenditure Outlook; 4.1.3. Emerging Countries Healthcare and Development Outlook; 4.2. Forecast Factors - Relevance & Impact; 4.2.1. Average Annual Spending on Pain Management Drugs; 4.2.2. Average Healthcare Expenditure; 4.2.3. Increasing Prevalence of Chronic and Acute Diseases; 4.2.4. Growing Number of Patients undergoing Surgical Interventions; 4.2.5. Rising Number of Population Suffering from End-stage Diseases; 4.2.6. Per Capita Pharmaceutical Expenditure; 4.2.7. Awareness for Pain Management Drugs; 4.2.8. Favourable Reimbursement Policies; 4.2.9. Regulatory Control over Prescription; 4.2.10. Popularity of Generic Products; 4.2.11. Patent Expiration of Novel Pain Management Drugs (Opioids); 4.2.12. Introduction of Novel Abuse-deterrent Pain Management Drugs; 4.3. Market Dynamics; 4.3.1. Drivers; 4.3.2. Restraints; 4.3.3. Trends; 4.3.4. Opportunity Analysis
5. Market Context: 5.1. Promotional and Marketing Strategies, By Key Services Providers; 5.2. Description of Industry Evolution and Main developments; 5.3. Regulatory Scenario; 5.4. Technological Evaluation and Advancements; 5.5. Key Industry Events; 5.6. Porter’s Five Force Analysis
6. COVID19 Crisis Analysis: 6.1. Current COVID19 Statistics and Probable Future Impact; 6.2. Current GDP Projection and Probable Impact; 6.3. Current Economic Projection as compared to 2008 financial analysis; 6.4. COVID19 and Impact Analysis; 6.4.1. Revenue By Drug Class; 6.4.2. Revenue By Route of Administration; 6.4.3. Revenue By Distribution Channel; 6.4.4. Revenue By Country; 6.5. 2022 Market Scenario; 6.6. Quarter by Quarter Forecast; 6.7. Projected recovery Quarter; 6.8. Recovery Scenario– Short term, Midterm and Long Term Impact
7. Global Postoperative Pain Management Market Value (US$ Mn) Analysis 2016-2021 and Forecast, 2022-2031: 7.1. Historical Market Value (US$ Mn) Analysis, 2016-2021; 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2031; 7.2.1. Y-o-Y Growth Trend Analysis; 7.2.2. Absolute $ Opportunity Analysis
8. Global Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031, By Drug Class: 8.1. Introduction / Key Findings; 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2016 - 2021; 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2022 - 2031; 8.3.1. Opioids; 8.3.2. NSAIDS; 8.3.3. Local Anaesthetics; 8.3.4. Acetaminophen; 8.4. Market Attractiveness Analysis By Drug Class
9. Global Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031, By Route of Administration: 9.1. Introduction / Key Findings; 9.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2016 - 2021; 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022 - 2031; 9.3.1. Injectable; 9.3.2. Oral; 9.3.3. Topical; 9.3.4. Transdermal; 9.3.5. Others; 9.4. Market Attractiveness Analysis By Route of Administration
10. Global Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031, By Distribution Channel: 10.1. Introduction / Key Findings; 10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2016 - 2021; 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 - 2031; 10.3.1. Hospital Pharmacies; 10.3.2. Retail Pharmacies; 10.3.3. Drug Store; 10.3.4. Clinics; 10.3.5. Others; 10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031, by Region: 11.1. Introduction; 11.2. Historical Market Size (US$ Mn) Analysis By Region, 2016 - 2021; 11.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2031; 11.3.1. North America; 11.3.2. Latin America; 11.3.3. Europe; 11.3.4. South Asia; 11.3.5. East Asia; 11.3.6. Oceania; 11.3.7. Middle East and Africa (MEA); 11.4. Market Attractiveness Analysis By Region
12. North America Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 12.1. Introduction; 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 12.3.1. By Country; 12.3.1.1. U.S.; 12.3.1.2. Canada; 12.3.2. By Drug Class; 12.3.3. By Route of Administration; 12.3.4. By Distribution Channel; 12.4. Market Attractiveness Analysis; 12.5. Key Market Participants - Intensity Mapping; 12.6. Drivers and Restraints - Impact Analysis
13. Latin America Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 13.1. Introduction; 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 13.3.1. By Country; 13.3.1.1. Brazil; 13.3.1.2. Mexico; 13.3.1.3. Argentina; 13.3.1.4. Rest of Latin America; 13.3.2. By Drug Class; 13.3.3. By Route of Administration; 13.3.4. By Distribution Channel; 13.4. Market Attractiveness Analysis; 13.5. Key Market Participants - Intensity Mapping; 13.6. Drivers and Restraints - Impact Analysis
14. Europe Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 14.1. Introduction; 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 14.3.1. By Country; 14.3.1.1. U.K.; 14.3.1.2. Germany; 14.3.1.3. France; 14.3.1.4. Italy; 14.3.1.5. Spain; 14.3.1.6. Russia; 14.3.1.7. BENELUX; 14.3.1.8. Rest of Europe; 14.3.2. By Drug Class; 14.3.3. By Route of Administration; 14.3.4. By Distribution Channel; 14.4. Market Attractiveness Analysis; 14.5. Key Market Participants - Intensity Mapping; 14.6. Drivers and Restraints - Impact Analysis
15. South Asia Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 15.1. Introduction; 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 15.3.1. By Country; 15.3.1.1. India; 15.3.1.2. Thailand; 15.3.1.3. Indonesia; 15.3.1.4. Malaysia; 15.3.1.5. Rest of South Asia; 15.3.2. By Drug Class; 15.3.3. By Route of Administration; 15.3.4. By Distribution Channel; 15.4. Market Attractiveness Analysis; 15.5. Key Market Participants - Intensity Mapping; 15.6. Drivers and Restraints - Impact Analysis
16. East Asia Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 16.1. Introduction; 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 16.3.1. By Country; 16.3.1.1. China; 16.3.1.2. Japan; 16.3.1.3. South Korea; 16.3.1.4. Rest of East Asia; 16.3.2. By Drug Class; 16.3.3. By Route of Administration; 16.3.4. By Distribution Channel; 16.4. Market Attractiveness Analysis; 16.5. Key Market Participants - Intensity Mapping; 16.6. Drivers and Restraints - Impact Analysis
17. Oceania Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 17.1. Introduction; 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 17.3.1. By Country; 17.3.1.1. Australia; 17.3.1.2. New Zealand; 17.3.2. By Drug Class; 17.3.3. By Route of Administration; 17.3.4. By Distribution Channel; 17.4. Market Attractiveness Analysis; 17.5. Key Market Participants - Intensity Mapping; 17.6. Drivers and Restraints - Impact Analysis
18. Middle East and Africa Postoperative Pain Management Market Analysis 2016-2021 and Forecast 2022-2031: 18.1. Introduction; 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2016 - 2021; 18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2031; 18.3.1. By Country; 18.3.1.1. GCC Countries; 18.3.1.2. Turkey; 18.3.1.3. Northern Africa; 18.3.1.4. South Africa; 18.3.1.5. Rest of Middle East and Africa; 18.3.2. By Drug Class; 18.3.3. By Route of Administration; 18.3.4. By Distribution Channel; 18.4. Market Attractiveness Analysis; 18.5. Key Market Participants - Intensity Mapping; 18.6. Drivers and Restraints - Impact Analysis
19. Emerging Countries Postoperative Pain Management Market Analysis 2022 & 2031: 19.1. Introduction; 19.1.1. Market Value Proportion Analysis, By Key Countries; 19.1.2. Global Vs. Country Growth Comparison; 19.2. U.S. Postoperative Pain Management Market Analysis; 19.2.1. By Drug Class; 19.2.2. By Route of Administration; 19.2.3. By Distribution Channel; 19.3. Canada Postoperative Pain Management Market Analysis; 19.3.1. By Drug Class; 19.3.2. By Route of Administration; 19.3.3. By Distribution Channel; 19.4. Mexico Postoperative Pain Management Market Analysis; 19.4.1. By Drug Class; 19.4.2. By Route of Administration; 19.4.3. By Distribution Channel; 19.5. Brazil Postoperative Pain Management Market Analysis; 19.5.1. By Drug Class; 19.5.2. By Route of Administration; 19.5.3. By Distribution Channel; 19.6. U.K. Postoperative Pain Management Market Analysis; 19.6.1. By Drug Class; 19.6.2. By Route of Administration; 19.6.3. By Distribution Channel; 19.7. Germany Postoperative Pain Management Market Analysis; 19.7.1. By Drug Class; 19.7.2. By Route of Administration; 19.7.3. By Distribution Channel; 19.8. France Postoperative Pain Management Market Analysis; 19.8.1. By Drug Class; 19.8.2. By Route of Administration; 19.8.3. By Distribution Channel; 19.9. Italy Postoperative Pain Management Market Analysis; 19.9.1. By Drug Class; 19.9.2. By Route of Administration; 19.9.3. By Distribution Channel; 19.10. Spain Postoperative Pain Management Market Analysis; 19.10.1. By Drug Class; 19.10.2. By Route of Administration; 19.10.3. By Distribution Channel; 19.11. BENELUX Postoperative Pain Management Market Analysis; 19.11.1. By Drug Class; 19.11.2. By Route of Administration; 19.11.3. By Distribution Channel; 19.12. Russia Postoperative Pain Management Market Analysis; 19.12.1. By Drug Class; 19.12.2. By Route of Administration; 19.12.3. By Distribution Channel; 19.13. China Postoperative Pain Management Market Analysis; 19.13.1. By Drug Class; 19.13.2. By Route of Administration; 19.13.3. By Distribution Channel; 19.14. Japan Postoperative Pain Management Market Analysis; 19.14.1. By Drug Class; 19.14.2. By Route of Administration; 19.14.3. By Distribution Channel; 19.15. South Korea Postoperative Pain Management Market Analysis; 19.15.1. By Drug Class; 19.15.2. By Route of Administration; 19.15.3. By Distribution Channel; 19.16. India Postoperative Pain Management Market Analysis; 19.16.1. By Drug Class; 19.16.2. By Route of Administration; 19.16.3. By Distribution Channel; 19.17. ASEAN Postoperative Pain Management Market Analysis; 19.17.1. By Drug Class; 19.17.2. By Route of Administration; 19.17.3. By Distribution Channel; 19.18. Australia Postoperative Pain Management Market Analysis; 19.18.1. By Drug Class; 19.18.2. By Route of Administration; 19.18.3. By Distribution Channel; 19.19. New Zealand Postoperative Pain Management Market Analysis; 19.19.1. By Drug Class; 19.19.2. By Route of Administration; 19.19.3. By Distribution Channel; 19.20. GCC Countries Postoperative Pain Management Market Analysis; 19.20.1. By Drug Class; 19.20.2. By Route of Administration; 19.20.3. By Distribution Channel; 19.21. Turkey Postoperative Pain Management Market Analysis; 19.21.1. By Drug Class; 19.21.2. By Route of Administration; 19.21.3. By Distribution Channel; 19.22. South Africa Postoperative Pain Management Market Analysis; 19.22.1. By Drug Class; 19.22.2. By Route of Administration; 19.22.3. By Distribution Channel
20. Market Structure Analysis: 20.1. Market Analysis by Tier of Companies; 20.2. Market Share Analysis of Top Players; 20.3. Market Concentration; 20.4. Market Presence Analysis; 20.4.1. By Regional footprint of Players; 20.4.2. Product foot print by Players; 20.4.3. Channel Foot Print by Players
21. Competition Analysis: 21.1. Competition Dashboard; 21.2. Competition Benchmarking; 21.3. Competition Deep Dive; 21.3.1. Teva Pharmaceutical Industries Ltd.; 21.3.1.1. Overview; 21.3.1.2. Services Portfolio; 21.3.1.3. Analyst Commentary; 21.3.1.4. Key Financials; 21.3.1.5. Recent Developments; 21.3.1.6. Sales Footprint; 21.3.1.7. Strategy Overview; 21.3.1.7.1. Marketing Strategy; 21.3.1.7.2. Services Strategy; 21.3.1.7.3. Channel Strategy; 21.3.2. Novartis AG; 21.3.2.1. Overview; 21.3.2.2. Services Portfolio; 21.3.2.3. Analyst Commentary; 21.3.2.4. Key Financials; 21.3.2.5. Recent Developments; 21.3.2.6. Sales Footprint; 21.3.2.7. Strategy Overview; 21.3.2.7.1. Marketing Strategy; 21.3.2.7.2. Services Strategy; 21.3.2.7.3. Channel Strategy; 21.3.3. Allergan plc; 21.3.3.1. Overview; 21.3.3.2. Services Portfolio; 21.3.3.3. Analyst Commentary; 21.3.3.4. Key Financials; 21.3.3.5. Recent Developments; 21.3.3.6. Sales Footprint; 21.3.3.7. Strategy Overview; 21.3.3.7.1. Marketing Strategy; 21.3.3.7.2. Services Strategy; 21.3.3.7.3. Channel Strategy; 21.3.4. Mylan N.V; 21.3.4.1. Overview; 21.3.4.2. Services Portfolio; 21.3.4.3. Analyst Commentary; 21.3.4.4. Key Financials; 21.3.4.5. Recent Developments; 21.3.4.6. Sales Footprint; 21.3.4.7. Strategy Overview; 21.3.4.7.1. Marketing Strategy; 21.3.4.7.2. Services Strategy; 21.3.4.7.3. Channel Strategy; 21.3.5. Pfizer Inc.; 21.3.5.1. Overview; 21.3.5.2. Services Portfolio; 21.3.5.3. Analyst Commentary; 21.3.5.4. Key Financials; 21.3.5.5. Recent Developments; 21.3.5.6. Sales Footprint; 21.3.5.7. Strategy Overview; 21.3.5.7.1. Marketing Strategy; 21.3.5.7.2. Services Strategy; 21.3.5.7.3. Channel Strategy; 21.3.6. Purdue Pharma L.P; 21.3.6.1. Overview; 21.3.6.2. Services Portfolio; 21.3.6.3. Analyst Commentary; 21.3.6.4. Key Financials; 21.3.6.5. Recent Developments; 21.3.6.6. Sales Footprint; 21.3.6.7. Strategy Overview; 21.3.6.7.1. Marketing Strategy; 21.3.6.7.2. Services Strategy; 21.3.6.7.3. Channel Strategy; 21.3.7. Janssen Pharmaceuticals, Inc.; 21.3.7.1. Overview; 21.3.7.2. Services Portfolio; 21.3.7.3. Analyst Commentary; 21.3.7.4. Key Financials; 21.3.7.5. Recent Developments; 21.3.7.6. Sales Footprint; 21.3.7.7. Strategy Overview; 21.3.7.7.1. Marketing Strategy; 21.3.7.7.2. Services Strategy; 21.3.7.7.3. Channel Strategy; 21.3.8. Endo International plc; 21.3.8.1. Overview; 21.3.8.2. Services Portfolio; 21.3.8.3. Analyst Commentary; 21.3.8.4. Key Financials; 21.3.8.5. Recent Developments; 21.3.8.6. Sales Footprint; 21.3.8.7. Strategy Overview; 21.3.8.7.1. Marketing Strategy; 21.3.8.7.2. Services Strategy; 21.3.8.7.3. Channel Strategy; 21.3.9. Pacira Pharmaceuticals Inc.; 21.3.9.1. Overview; 21.3.9.2. Services Portfolio; 21.3.9.3. Analyst Commentary; 21.3.9.4. Key Financials; 21.3.9.5. Recent Developments; 21.3.9.6. Sales Footprint; 21.3.9.7. Strategy Overview; 21.3.9.7.1. Marketing Strategy; 21.3.9.7.2. Services Strategy; 21.3.9.7.3. Channel Strategy; 21.3.10. Egalet Corporation; 21.3.10.1. Overview; 21.3.10.2. Services Portfolio; 21.3.10.3. Analyst Commentary; 21.3.10.4. Key Financials; 21.3.10.5. Recent Developments; 21.3.10.6. Sales Footprint; 21.3.10.7. Strategy Overview; 21.3.10.7.1. Marketing Strategy; 21.3.10.7.2. Services Strategy; 21.3.10.7.3. Channel Strategy; 21.3.11. GlaxoSmithKline Plc.; 21.3.11.1. Overview; 21.3.11.2. Services Portfolio; 21.3.11.3. Analyst Commentary; 21.3.11.4. Key Financials; 21.3.11.5. Recent Developments; 21.3.11.6. Sales Footprint; 21.3.11.7. Strategy Overview; 21.3.11.7.1. Marketing Strategy; 21.3.11.7.2. Services Strategy; 21.3.11.7.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology